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HIV clinical markersChronic systemic immune activation and inﬂammatory processes have been linked to brain dysfunction inmed-
ically stable HIV-infected people. We investigated the association between verbal memory performance and
plasma concentrations of 13 cytokines measured using multiplexed bead array immunoassay in 74 HIV-
seropositive individuals and 50 HIV-seronegative controls. Memory performance was positively related to levels
of IL-8 and IFN-γ, and negatively related to IL-10 and IL-18 and to hepatitis C infection.Memory performancewas
not signiﬁcantly related to HIV disease markers. The results indicate the importance of systemic immune and
inﬂammatory markers to neurocognitive function in chronic and stable HIV disease.
© 2013 Published by Elsevier B.V.1. Introduction
The widespread availability and use of combination antiretroviral
therapy (CART) over the past decade has resulted in dramatic reduc-
tions in mortality (Yeni, 2006) and improved cognitive status among
many HIV-infected individuals (Cohen et al., 2001; Robinson-Papp
et al., 2009). Yet, cognitive impairments remain prevalent affecting up
to 50% of HIV-infected individuals in the United States (Heaton et al.,
2011; Schouten et al., 2011), even among those with good HIV control
on CART (Cysique and Brew, 2011; Garvey et al., 2011). The cognitive
domains most commonly affected by HIV include psychomotor speed,
attention, and executive functions (Grant, 2008). Memory, particularly
impaired learning and retrieval of new information, is also affected
(Woods et al., 2009). This pattern of memory performance is typically
suggestive of disruption of subcortical memory and executive circuits
rather than hippocampal involvement, which typically produces an
amnestic pattern characterized by rapid forgetting as in Alzheimer'sg and Memory, University of
1329 SW 16th St., Suite 5251,
vier B.V.disease (Dickerson and Eichenbaum, 2010). The reasons for persistence
of cognitive dysfunction in the CART era are not well understood. One
possibility relates to adverse cerebral neuronal impact of altered cyto-
kine expression due to chronic infection-related inﬂammation and im-
mune activation (Langford and Masliah, 2001; Si et al., 2002; Sui et al.,
2003; Woods et al., 2006; Cohen et al., 2011).
The cerebral pathophysiology of HIV supports a link between in-
ﬂammatory cytokines and cognitive dysfunction in HIV. HIV enters the
brain soon after infection, triggering inﬂammatory responses associated
with microglial activation and associated release of neurotoxic pro-
inﬂammatory cytokines and chemokines (Gisolf et al., 2000; Rostasy
et al., 2000; Gonzalez-Scarano and Martin-Garcia, 2005; Shah and
Kumar, 2010; Shah et al., 2011a,b; Silverstein et al., 2012), which are
thought to contribute importantly to neuronal injury and protection in
HIV (Merrill and Chen, 1991; Gray et al., 1996; He et al., 1997; Kaul
and Lipton, 1999; Krebs et al., 2000; Thompson et al., 2001; Minagar
et al., 2002; Okamoto et al., 2003; Sabri et al., 2003; Albright and
Gonzalez-Scarano, 2004; Barber et al., 2004; Kim et al., 2004; Nukuna
et al., 2004; Poluektova et al., 2004; Potula et al., 2004; Cartier et al.,
2005; Chiodi, 2006; Gorg et al., 2006; Guyon et al., 2008; Lewis et al.,
2008; Sas et al., 2009). Studies using magnetic resonance spectroscopy
(MRS) provide evidence of adverse inﬂammatory impact on brain
Table 1
Demographic and clinical characteristics of study participants.
HIV− HIV+
HCV− HCV+ HCV− HCV+
N 45 5 50 24
Age (years) 46.67
(14.69)
40.2
(10.03)
45 (10.16) 49.17 (7.39)
Education (years) 14.22
(3.46)
13.00
(2.35)
13.06 (2.14) 11.67 (1.66)
Sex (% male) 27 (60%) 3 (60%) 34 (68%) 14 (58%)
Ethnicity
(% Caucasian)
35 (78%) 3 (60%) 32 (64%) 9 (38%)
Current CD4
(cells/μl)
528.83
(254.69)a
471.81
(338.04)b
Nadir CD4 (cells/μl) 187.15
(166.88)c
148.7
(134.91)d
Duration of HIV
infection (years)
12.1 (6.45)e 16.5 (6.72)f
Undetectable plasma HIV
RNA (%)
33 (73%)g 17 (77%)h
CART-treated (%) 42 (88%)i 21 (88%)j
Note: Continuous variables are reported as mean (SD). Proportions are reported as N (%).
Analyses involving HIV clinical variableswere conducted only in caseswith complete data
for all variables.
a n = 47.
b n = 21.
c n = 48.
d n = 23.
e n = 48.
f n = 24.
g n = 45.
h n = 22.
i n = 48.
j n = 24.
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2008), particularly in basal ganglia and frontal brain regions (Paul et al.,
2008; Cohen et al., 2010). These metabolic changes in frontal–
subcortical circuits alignwith the cognitive proﬁle of prominent attention
and executive dysfunction in HIV and the subcortical pattern of memory
difﬁculties characterized by encoding and retrieval impairments.
Our group (Cohen et al., 2011) recently demonstrated direct evidence
that plasma cytokine levels are associated with attention and executive
function in individuals with HIV infection. Further, our results showed
that these cytokines were retained in statistical models predicting dys-
function in these cognitive domains even when HIV clinical markers
such as HIV RNA level and duration of illness were included in the statis-
tical model. These results, viewed in the context of aforementionedMRS
studies, raise the possibility that altered cytokine expression might also
contribute to HIV-related memory impairment.
We addressed this possibility by examining the association between
plasma cytokine levels and verbal memory functioning in individuals
with andwithout HIV.We hypothesized that abnormal plasma cytokine
levels are associated with reduced learning and memory performance
even among HIV individuals with adequately reconstituted immune
systems.
Our goal was to determine if systemic inﬂammatory and immuno-
logical processes inﬂuence learning and memory impairments, and to
identify potential cytokine biomarkers that may be useful for assessing
HIV-associated neurocognitive impairment. Understanding the role of
cytokines in HIV-related cognitive dysfunction, particularly if the rela-
tionship can be detected using plasma cytokine levels would provide
researchers and clinicians with an easily accessed and inexpensive bio-
marker for predicting and monitoring cognitive dysfunction in HV. This
information could be very useful in helping individual patients plan for
their long-term care and in assessing the efﬁcacy of new treatments to
reduce cognitive decline in HIV.
2. Methods
2.1. Participants
Participants were 124 adults including 74 HIV-infected (HIV+) and
50 HIV seronegative (HIV−) individuals. Participants were between 24
and 79 years of age (mean = 46.22 ± 11.65 years). There were 78
men and 46 women. Participants were recruited between 2007 and
2010 as part of an NIH-sponsored study of HIV-associated brain dys-
function at The Miriam Hospital/Brown University. The Institutional
Review Boards at Miriam Hospital and Brown University approved the
study, and informed consent was obtained from each participant prior
to enrollment. Exclusion criteria included 1) history of head injury
with loss of consciousness N10 min; 2) neurological conditions includ-
ing dementia unrelated toHIV, seizure disorder, stroke, and opportunis-
tic infection of the brain; 3) severe psychiatric illness that may impact
brain function, e.g., schizophrenia; and 4) substance use disorderwithin
6 months prior to neuroimaging.
HIV serostatuswas documented by ELISA and conﬁrmed byWestern
blot test. A signiﬁcant number of participants including 24 HIV+ (32%)
and 5 HIV− (10%) individuals had current hepatitis C infection
(HCV+), deﬁned as detectable serum HCV RNA by PCR. Viral load
(HIV RNA by PCR) was classiﬁed as detectable or undetectable based
on a lower limit of detection of 75 copies/ml. Most HIV+ participants
(67.6%) had undetectable viral loads (n = 67), and 83.3% were on sta-
ble CART. Nadir CD4 count was available on 71 of the 74 HIV+ partici-
pants. Of these more than half (61%) reported nadir CD4 b 200 and
average nadir CD4was 174.7 ± 157.3 cells/μl indicating a history of sig-
niﬁcant immune suppression. Two of the individuals without nadir CD4
were also missing duration of HIV infection and we were unable to
assess CART status. The duration of HIV infection (n = 72) ranged
from 1 to 26 years. Current CD4 was unavailable on 6 HIV participants
including 3 with missing nadir CD4. Most (70.6%) HIV-infected subjectshad reconstituted immune function as indicated by current CD4
counts above 350 cells/μl (n = 68). Demographic characteristics
stratiﬁed by HIV and HCV status are presented in Table 1. Age and
group sex composition did not differ signiﬁcantly by HIV status
(age, p = .969; sex, p =.479) or by current HCV status (age, p =
.472; sex, p = .481). The HIV−/HCV− group had signiﬁcantly more
years of education compared to the HIV+/HCV+ group (p = .001).
2.2. Cytokine measurement
Plasma was separated from each participant's blood sample and
immediately frozen and stored at −80 °C. Chemokine and cytokine
levels were measured using an xMAPmultiplexed bead array immuno-
assay with ﬂuorescence intensity measured using the Luminex-100
system (Luminex Corp., Austin, TX). Samples were diluted 1:5 in reac-
tion buffer according to the manufacturer's protocol. All samples were
treated identically and all assays were performed simultaneously using
the same platforms and reagents. The panel of cytokines used along
with their proposed functions is listed in Table 2. All cytokine assay
results fell within the linear dynamic range of the standards (ﬂuores-
cent light units per milliliter = FLU/ml). However, the data were natu-
ral log transformed to reduce variance and outliers within the groups.
Bivariate correlations were used to determine if participant demo-
graphics were correlated with cytokine levels in the entire sample.
Age did not correlate signiﬁcantly with any of the 13 cytokines (maxi-
mum r = .112, p = .216). Education was signiﬁcantly and negatively
associated with IL-8 only (r = − .193, p = .032) but this did not sur-
vive correction for multiple comparisons.
2.3. Neuropsychological measures
All participants completed the Hopkins Verbal Learning Test —
Revised (HVLT-R) (Benedict et al., 1998), a widely used standardized
test with extensive norms and strong reliability and validity. The
HVLT-R is a test of verbal memory involving immediate recall of a 12-
Table 2
Descriptions of cytokines and chemokines measured in this studya.
Cytokine/chemokine Abbreviation Function
Interferon gamma-soluble cytokine IFN-γ Produced by innate NK cells, acquired antigen-speciﬁc cytotoxic CD4 + and effector CD8 + T cells. Activates
macrophages and critical for innate and adaptive immune responses to intracellular pathogens, tumor control, and
inhibition of viral replication.
Interleukin-1-beta IL-1β Produced by activatedmacrophages; mediates inﬂammatory responses, cell proliferation, apoptosis. Induces Cox-2 in
CNS, causing inﬂammatory pain
Interleukin-6 IL-6 Secreted by T cells and macrophages; triggers inﬂammation, acute phase response, fever. Anti-inﬂammatory effects
include inhibiting TNF-α and IL-1, and activating IL-1ra and IL-10.
Interleukin-8 IL-8 Made by macrophages and some epithelial and endothelial cells; role in innate immune response.
Major role in chemotaxis of neutrophils. Also mediates inﬂammatory response and angiogenesis.
Interleukin-10 IL-10 Produced by monocytes. Pleiotropic cytokine. As an anti-inﬂammatory cytokine, it inhibits macrophage and dendritic
cell function, suppresses TNF-α. Acquires pro-inﬂammatory activity during immune responsewith IFN-α stimulation.
Interleukin-16 IL-16 Secreted by lymphocytes. Pleiotropic cytokine. Functions as a chemoattractant (CD4 + cells), modulates T cell
activation, and inhibits HIV replication.
Interleukin-18 IL-18 Produced by macrophages and monocytes. Pro-inﬂammatory cytokine interacts with IL-12 to induce cell-mediated
immune response withmicrobial infection and LPS, inducing severe inﬂammatory reactions. Stimulates NK and T cell
release of IFN-γ, which activates macrophages. Inhibits IL4-dependent IgE, enhances B cell production.
Interferon-inducible protein-10 IP-10 Produced by various cell types including monocytes, endothelial cells, ﬁbroblasts, keratinocytes. Induced by IFN-γ
and TNF-α. Chemoattractant for activated T cells.
Monocyte chemoattractant protein-1 MCP-1 Expressed in monocytes, vascular endothelial cells, smooth muscle cells. CCL2 chemokine, induces monocyte
attraction, and degranulation of basophils with histamine release. Induced by IL-1, TNF-α, PDGF, TGF-β, and LIF
Macrophage inﬂammatory protein-1-beta MIP-1β Produced by macrophages. CCL4 chemokine that generates local inﬂammatory responses, induces superoxide
production by neutrophils. Chemotactic activity for lymphocytes, macrophages, NK cells, and monocytes with
inﬂammation; down-regulates CCR5, inhibiting HIV-1 blocking.
Stromal cell-derived factor-1-alpha SDF-1α Expressed ubiquitously, except in blood cells. Small cytokine member of CXCL12 family of chemokines. Activates
leukocytes due to strong chemotactic effects. Induced by pro-inﬂammatory stimuli, e.g. TNF-α and IL-1β.
Tumor necrosis factor-alpha TNF-α Secreted by macrophages, monocytes, neutrophils, T cells, NK cells after stimulation with LPS. CD4 + cells
secrete TNF-α. Also made by astrocytes, microglial cells, smooth muscle cells, and ﬁbroblasts. Mediates systemic
inﬂammation, inhibits viral replication, and inhibits tumorigenesis.
Tumor necrosis factor related
apoptosis-inducing ligand
TRAIL Expressed broadly in tissues. Cytokine induces proapoptotic caspase activity by up-regulating pro-apoptotic Bcl
proteins. Causes apoptosis in hepatocytes, neural cells, and thymocytes.
a Reproduced from Cohen et al. (2011).
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afterwhich the examinee calls out asmanywords as he or she can recall
in any order. Three trials are administered. The delayed recall phase
starts 20 min later. Examinees are asked to recall the word list. This
free recall trial is followed by a forced-choice recognition recall trial.
Scores used in this analysis are (1) immediate recall: the total number
of recalled words summed across the three learning trails and (2) de-
layed recall: the number of words recalled after the 20-minute delay.
The HVLT-R immediate and delayedmemory scores have demonstrated
sensitivity to HIV-related verbal memory impairment (Woods et al.,
2005). The immediate and delayed recall raw scores were transformed
into age-corrected T-scores using the norms provided in the published
test manual. T-scores were used as dependent measures in subsequent
analyses. T-scores have a mean of 50 and standard deviation of 10. For
the purpose of the current analysis, higher T-scores indicate better
performance.
2.4. Statistical analysis
All statistical analysis was performed in R, version 2.12.1 (http://
www.r-project.org) and SPSS version 20 (http://www-01.ibm.com/
software/analytics/spss/). To examine HIV+/− group differences in
plasma concentrations of the 13 cytokines, we used multivariate
ANCOVA covarying for current HCV status with follow-up univariate
ANOVAs.
To examine the relationship between the plasma cytokine con-
centrations and performance on the two memory measures (HVLT-
R immediate and delayed recall T scores), we used the Akaike Infor-
mation Criterion (AIC) (Akaike, 1974; Burnham and Anderson, 2002)procedure. The procedure is a linear regression model-selection algo-
rithm that balances model ﬁt with complexity to identify a parsimoni-
ous set of independent variables that predict a dependent variable.
Four model-selection procedures were run. The ﬁrst two were run
using the whole sample. Independent variables for these models were
HIV and HCV status, and all 13 cytokines as independent variables. De-
pendent variables were HVLT-R immediate recall in the ﬁrst model and
delayed recall in the second. The next two model-selection procedures
were run in the HIV + group only. Independent variables were CD4
nadir (log transform), current CD4 count, HIV RNA level, duration of
HIV infection, and CART status as a dichotomous variable (i.e., yes/no).
Dependent measures were HVLT-R immediate and delayed recall
scores.
3. Results
3.1. HIV effects on cytokine concentrations
Plasma cytokine levels by group stratiﬁed by HIV and HCV status are
presented in Table 3 and graphically presented in Fig. 1. We used
MANCOVA to assess the impact of HIV status on cytokine concentration
incorporating current HCV status as a covariate. Neither age nor educa-
tion was included in this analysis due to the absence of signiﬁcant asso-
ciations between them and cytokine levels. Results showed a signiﬁcant
main effect of HIV (Pillai's trace = 0.285, F(13, 109) = 3.340, p b .001,
partial η2 = .285) and HCV status (Pillai's trace = 0.378, F(13, 109) =
5.100, p b .001, η2 = .378) on cytokine concentrations. Follow-up uni-
variate analyses of the effect of HIV status, controlled for HCV status,
showed signiﬁcant HIV group differences on 4 of the 13 cytokines.
Table 3
Plasma cytokine levels stratiﬁedbyHIV andHCV status. Values are log transformed FLU/ml
displayed as mean (SD); (95% conﬁdence interval).
HIV− HIV+
Cytokine HCV−
n = 45
HCV+
n = 5
HCV−
n = 50
HCV+
n = 24
IFN-γ 1.57 (0.78)
(1.33–1.80)
1.58 (0.15)
(1.39–1.77)
1.44 (0.51)
(1.30–1.59)
1.37 (0.53)
(1.15–1.59)
IL-1β 1.85 (0.48)
(1.71–1.99)
2.07 (0.46)
(1.50–2.64)
1.99 (0.49)
(1.85–2.13)
2.00 (0.52)
(1.79–2.22)
IL-6 2.13 (0.62)
(1.94–2.32)
2.37 (0.5)
(1.76–2.99)
2.19 (0.69)
(1.99–2.38)
2.34 (0.64)
(2.07–2.61)
IL-8 2.79 (0.45)
(2.65–2.92)
3.13 (0.5)
(2.50–3.75)
3.11 (0.55)
(2.95–3.27)
3.33 (0.62)⁎
(3.07–3.59)
IL-10 2.86 (0.37)
(2.75–2.97)
3.3 (0.48)
(2.70–3.90)
2.87 (0.26)
(2.80–2.95)
3.03 (0.4)
(2.86–3.20)
IL-16 4.2 (0.54)
(4.04–4.36)
4.14 (0.77)
(3.19–5.10)
3.99 (0.47)
(3.86–4.12)
4.1 (0.51)
(3.88–4.31)
IL-18 3.96 (0.65)
(3.76–4.15)
4.22 (0.65)
(3.41–5.03)
4.44 (0.86)
(4.20–4.69)
4.62 (0.91)⁎
(4.23–5.00)
IP-10 5.04 (0.83)
(4.79–5.29)
5.97 (1.29)
(4.37–7.57)
5.61 (1.05)
(5.31–5.91)
7.21 (0.82)⁎⁎
(6.87–7.56)
MCP-1 4.85 (0.70)
(4.64–5.06)
5.41 (0.59)
(4.67–6.15)
4.95 (0.73)
(4.74–5.16)
4.66 (0.75)
(4.34–4.98)
MIP-1β 3.65 (0.82)
(3.41–3.90)
4.37 (1.11)
(2.99–5.75)
3.93 (0.78)
(3.71–4.15)
4.8 (0.89)⁎
(4.42–5.17)
SDF-1α 2.99 (0.6)
(2.81–3.17)
2.86 (0.49)
(2.25–3.46)
2.77 (0.38)
(2.66–2.87)
2.76 (0.37)
(2.61–2.92)
TNF-α 1.81 (0.36)
(1.70–1.92)
2.02 (0.33)
(1.61–2.44)
1.88 (0.43)
(1.75–2.00)
1.94 (0.41)
(1.76–2.11)
TRAIL 3.43 (0.50)
(3.28–3.58)
3.63 (0.33)
(3.21–4.03)
3.5 (0.46)
(3.37–3.62)
3.58 (0.55)
(3.35–3.81)
⁎ mean value is greater than 1 standard deviation discrepant frommean value of HIV−/
HCV− group.
⁎⁎ mean value is greater than 2 standard deviations discrepant frommean value of HIV−/
HCV− group.
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higher levels of IL-8 (p = .003), IL-18 (p = .002), IP-10 (p b .001),
and signiﬁcantly lower SDF-1α (p = .025). Statistical trends occurred
toward higher MIP-1β and lower IL-6 (p = .061) in the HIV + group.
3.2. Cytokines and cognitive function
Table 4 shows results of a linear regression model-selection algo-
rithm run in the entire sample and in the HIV+ group only to identify
parsimonious models predicting cognitive status as described in the
Methods section. We did not include age or sex because the groups
did not differ on these variables; moreover, memory T-scores already
include a correction for age. We did not include education in these
models because correlations between education and cytokine levels
were non-signiﬁcant after correction formultiple tests. Accordingly, ed-
ucation is unlikely to moderate an association between cytokines and
memory.
3.2.1. Whole group
In the entire sample, predictor variables included the 13 cytokines,
HIV status, and HCV status, and education.
HVLT-R immediate recallwaspositively associatedMCP-1 (p = .011)
and negatively associated with IP-10 (p = .002).
HVLT-R delayed recallwas positively associatedwith IL-8 (p = .048)
and negatively associated with both HIV and current HCV infections
(p = .015, p = .034, respectively).3.2.2. HIV+ only
Predictor variables in the regression models for the HIV+ group
only included the 13 cytokines, HCV status, the following HIV clinical
variables: CD4 nadir (log transformed), current CD4 count, HIV RNA
load (detectable vs. not detectable), HIV duration, and CART status
(yes/no).
HVLT-R immediate recall was positively associated with IL-8 (p =
.027), and negatively associated with IL-10 (p = .036) and HCV
infection (p = .020). There was a statistical trend toward positive
association with TNF-α (p = .093).
HVLT-R delayed recall was positively associated with IFN-γ (p =
.005) and IL-8 (p = .008) and negatively associated with IL-18
(p = .050) and current HCV infection (p = .007). There were
trends toward negative associations with detectable HIV RNA level
(p = .057) and CART status (p = .084).
4. Discussion
This study examined the associations between verbal learning and
memory and a panel of plasma cytokine measures and clinical markers
in the context of HIV infection.We used amodel-selection procedure to
identify which cytokines are most relevant to learning and memory
functions. Our main ﬁnding is that a number of cytokines are signiﬁ-
cantly associated with verbal memory ability in patients with HIV.
Higher levels of IL-8 and IFN-γwere associatedwith better performance
on memory measures. In contrast, higher IL-10 and IL-18 levels, and
HCV infection were related to poorer memory performance.
There was an additional positive statistical trend between TNF-α
and delayed recall. In contrast, traditional clinical markers of HIV status
including CD4 nadir and CD4 countwere not retained in the ﬁnal statis-
tical models. There were statistical trends toward poorer delayed verbal
recall among individuals with detectable HIV RNA viral load and among
those on CART. We also found an additional adverse impact of HCV sta-
tus on verbalmemory in this group. Agewas not signiﬁcantly associated
with cytokines. Education was also not signiﬁcantly associated with
cytokines after correction for multiple correlations.
In the combined group of HIV+ and HIV− individuals, immediate
verbalmemorywas associatedwithMCP-1 and IP-10 and delayed recall
was associated with IL-8. HIV infection negatively impacted delayed
verbal memory only. Current HCV infection impacted delayed, but not
immediate verbal memory.
In this HIV+ group, none of the clinical HIV variables were signiﬁ-
cantly associated withmemory performance. Of these clinical variables,
only HIV RNA level and CART status showed trend-level associations
with delayed verbal memory. These results provide evidence that a
group of inﬂammatory cytokines measured in plasma predict memory
performance in a group of HIV patients with well-reconstituted im-
mune systems. The results also indicate that cytokines remain signiﬁ-
cant predictors of memory status even when standard clinical HIV
markers were considered simultaneously in the statistical model.
These results extend prior work in this area and advance under-
standing of the impact of cytokine concentrations on neurocognitive
functioning in HIV-infected individuals (Cohen et al., 2011). Our prior
paper reported signiﬁcant associations between a subset of the same
13 cytokines and performances on tests of attention and executive func-
tion in HIV-infected individuals. The total number of cytokines showing
signiﬁcant associations in that analysis was greater than the number
signiﬁcantly associated with memory in the current analysis suggesting
fewer cytokines impact memory function in HIV than impact attention
and executive function in HIV. The prior study found that the associa-
tions were more common for the interleukins. The current results
align with this ﬁnding in that three of the four cytokines signiﬁcantly
associated withmemory function in the HIV+ groupwere interleukins.
At least one of the interleukins (IL-1β) has been shown to mediate
Fig. 1.Mean cytokine levels, expressed as log FLU/ml, in the three clinical groups (light gray), displayed in comparison to the 95% conﬁdence intervals of cytokine levels in the control group
(HIV−/HCV−; dark gray).
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of mediation is not understood (Huang and Sheng, 2010) nor is it clear
that this effect of IL-1β extends to other interleukins.
Our results show robust associations between HCV infection and
verbal memory. This is not unexpected given the prior work of
Huckans et al. (2009). Nearly all of those in our sample with HCV infec-
tion were also infected with HIV (45 co-infected, 5 mono-infected with
HCV), which raises some question about the independence of the effect
of HCV on memory in the absence of HIV. Unfortunately, our sample of
people with HCV who were not also infected with HIV is too small to
investigate this statistically.
HIV RNA viral load and CART treatment were the only HIV clinical
variables to enter any AIC model. This occurred only for delayed verbal
recall. The association was in the expected direction for HIV RNA level
but was in the opposite direction for CART. This CART ﬁnding is not
entirely unexpected in that others have reported decreased cognitive
function in the presence of CART (Robertson et al., 2010; Heaton et al.,
2011; Schouten et al., 2011).
Our results show that the association between plasma cytokine con-
centrations andmemory functioning occurs partly independently of tra-
ditional clinical markers of HIV-infection status and demographic
factors. Statistical analyses in the HIV+ group retained cytokines in
the most parsimonious models predicting performance on a widely
used verbal memory measure even when HCV status and HIV clinical
factorswere included as potential predictors. This result alignswithpre-
vious recent reports showing that cognitive impairmentwas not associ-
ated with HIV clinical markers in patients with good HIV control
(Cysique and Brew, 2011; Garvey et al., 2011). Our result, considered
with those of Cysique et al. and Garvey et al. raise the possibility that,
compared to plasma cytokine levels, traditional clinical HIV markers
may be less robust predictors of neurocognitive status in HIV patients
with well-reconstituted immune status.
Interestingly, cytokines were associated with immediate verbal
recall in the entire sample (HIV+ and HIV− groups combined), even
when HIV status itself was not retained in the ﬁnal statistical model.This latter ﬁnding tentatively suggests that cytokines inﬂuencememory
performance even in the absence of HIV. Alternatively, it is possible that
the association between cytokines and immediate verbal recall is a func-
tion of our speciﬁc sample of HIV− individuals. Clearly the inﬂuence of
cytokines on memory independent of HIV infection requires additional
study in a larger sample.
Cytokine concentrations differed as both functions of both HIV and
HCV status suggesting that both HIV and HCV infections affect systemic
inﬂammatory cytokine production. Alterations of serum and CSF cyto-
kine concentrations (e.g., MCP-1, IL-6, TNF-α) among people infected
with HIV are well documented in past studies (Laurenzi et al., 1990;
Lokensgard et al., 1997; Persidsky et al., 1997; Schoeniger-Skinner
et al., 2007), with elevated concentrations of speciﬁc concentrations
associated with increased neurovirulence (Na et al., 2011), pro-
inﬂammatory response in the brain (Feuerstein et al., 1994;
Sawada et al., 2006; Alcendor et al., 2012), and reduced cognitive
functioning (Cohen et al., 2011). Although they have received less
attention, cytokine disturbances also occur secondary to HCV (Huang
et al., 1999; Hung et al., 2009; Lemmers et al., 2009; Zhang et al.,
2011; Nishitsuji et al., 2013). The current ﬁndings suggest that HIV
and HCV may differentially affect certain cytokines, but also have simi-
lar effects on others. People with HIV had elevated concentrations of IL-
8, IL-18, and IP-10, and reduced concentrations of SDF-1α. HCV co-
infection was associated with over a two standard deviation increase
in IL-10 and one standard deviation increases in IL-8, IL-18, and MCP-
1. The conﬁdence intervals provided in Table 3 provide reference ranges
for evaluating the degree to which cytokines concentrations within in-
dividual patients infected with HIV with or without HCV co-infection
are abnormal relative to healthy people without either HIV or HCV.
These results are not intended for clinical application at this time. This
will eventually require validation studies to determine the consistency
of observed cytokine concentrations measured across different laborato-
ries andaccounting for use of equipment and reagents producedbydiffer-
ent vendors. The current preliminary ﬁndings show that a cytokine panel
such as the one employed in the current study can provide information
Table 4
Regression coefﬁcients and associated p-values for clinical and cytokine markers included
in the ﬁnal model selected by minimizing AIC for each HVLT-R immediate and delayed
recall scores in thewhole group and in the HIV+ group only. Rows indicate the predictors
under consideration, and each ﬁnal regression model is represented by one column of the
table. Statistically signiﬁcant covariates are highlighted in bold. Adjusted R2 values of the
ﬁnal models are included in the ﬁnal rows.
Whole group HIV+ only
HVLT-R
Immediate
recall
HVLT-R
Delayed
recall
HVLT-R
Immediate
recall
HVLT-R
Delayed
recall
HIV+ status −6.622
(0.015)
Current CD4
HIV RNA level −3.815
(0.148)
−7.031
(0.057)
CART+ −8.021
(0.084)
HIV duration
CD4 nadir
Current HCV+ −6.515
(0.034)
−6.019
(0.020)
−10.194
(0.007)
IFN-γ 10.506
(0.005)
IL1-β
IL6
IL8 5.353
(0.048)
5.274
(0.027)
−8.444
(0.008)
IL10 −10.699
(0.036)
−8.177
(0.118)
IL16
IL18 −3.314
(0.050)
IP10 −2.640
(0.002)
2.040
(0.186)
MCP1 3.658
(0.011)
MIP1-β 2.900
(0.134)
SDF1-α
TNF-α 6.323
(0.093)
TRAIL
ICV
Model adjusted R2 0.086 0.132 0.213 0.383
Note: Cell values are unstandardized regression coefﬁcient (p-value).
122 S. Correia et al. / Journal of Neuroimmunology 265 (2013) 117–123about the concentrations of particular cytokines relative to normative
values, which can eventually be clinically useful in detecting individuals
with signiﬁcant systemic inﬂammation secondary to HIV and HCV.
In sum, our results extend current understanding of the role of cyto-
kines on cognitive function in individualswithHIV infection.When con-
sidered along with our previous ﬁndings, our results suggest that
among HIV patients with good immune function, plasma cytokine con-
centration adds incrementally to the prediction of cognitive function,
over and above the contribution of clinical HIV markers. These prelimi-
nary results are not intended for clinical application at this time. Rather,
they suggest that plasma cytokine levels, which can be easily accessed
and measured reasonably inexpensively may, in the future, be helpful
for treatment planning; speciﬁcally for identifying patients at risk of
memory problems. They may also be helpful for selecting participants
for new interventions aimed at minimizing or reversing the impact of
HIV on cognitive function. However, such applications would require
replication of these results in other samples of HIV-infected patients
using cross-sectional and longitudinal designs to establish reliability
and validity.
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